http://repository.usmf.md:80/xmlui/handle/20.500.12710/12303 Sun, 12 Apr 2026 17:56:06 GMT 2026-04-12T17:56:06Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/16554 The Moldovan Medical Journal. December 2019, Vol. 62, No 4 The Moldovan Medical Journal is an international scientific double-blind peer reviewed periodical edition, 4 per year, of the Scientific Medical Association of the Republic of Moldova designed for specialists in the areas of medicine, dentistry, pharmacy, social medicine and public health. From its debut the journal has striven to support the interests of Moldovan medicine concerning the new concepts of its development. The Editorial Board warmly welcomes both the readers of and the authors for the journal, all those who are enthusiastic in searching new and more effective ways of solving numerous medicine problems. We hope that those who want to make their contribution to the science of medicine will find our journal helpful and encouraging. Fondatori: Ministerul Sănătăţii al Republicii Moldova, Universitatea de Stat de Medicină şi Farmacie “Nicolae Testemiţanu” Tue, 01 Jan 2019 00:00:00 GMT http://repository.usmf.md:80/xmlui/handle/20.500.12710/16554 2019-01-01T00:00:00Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/15274 Bone marrow-derived mononuclear cells therapy for ischemic stroke Butucel, Petru; Nacu, Viorel; Lisnic, Vitalie Background: Nowadays, the cerebrovascular event is the second cause of death and the third cause of disability worldwide. In the last few decades, stem cell-based approaches are widely analyzed as a potential treatment for this disease. One of these types of cells are bone marrow-derived mononuclear cells (BMMNCs). In this review, we analyzed 9 completed clinical trials with the use of BMMNCs in patients with ischemic stroke, which we found in the clinicaltrials. gov and PubMed databases, using the keywords “stroke“ and “bone marrow mononuclear cells”. Our goal was to analyze the safety and efficiency of this therapeutic approach, as well as the optimal therapeutic time window, transplantation route and cell dose used. The best stroke phase to apply this therapy is the subacute stage. Higher numbers of CD34+ cells, derived from BMMNCs were correlated with a trend toward a better outcome. All the clinical trials support the idea that BMMNCs transplantation is a safe therapy. Conclusions: In conclusion the author points out that the autologous transplantation of BMMNCs is harmless and not associated with severe complications. Although some clinical studies stated a better outcome in patients treated with BMMNCs, further clinical trials are needed to establish their therapeutic efficiency Laboratory of Tissue Engineering and Cells Culture, Department of Neurology No 1, Nicolae Testemitsanu State University of Medicine and Pharmacy, Chisinau, the Republic of Moldova Tue, 01 Jan 2019 00:00:00 GMT http://repository.usmf.md:80/xmlui/handle/20.500.12710/15274 2019-01-01T00:00:00Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/15272 Direct-acting antivirals: a new strategy in the treatment of hepatitis C virus infection in patients with cirrhosis Avricenco, Mariana Background: Hepatitis C virus (HCV) infection has a significant worldwide impact. Patients with hepatic cirrhosis with HCV have an annual risk of decompensation of 3-5%, a risk of developing hepatocellular carcinoma between 1.4-6.9% and a risk of mortality of 2% / year. Therefore, the treatment of chronic HCV infection is a priority for patients with severe hepatic fibrosis and cirrhosis. The emergence and approval of direct-acting antivirals (DAA) in recent years have revolutionized antiviral therapy, especially for patients with liver cirrhosis. Following numerous studies it has been found that, this treatment is well tolerated by these patients. The combination of DAA from different groups has a potent enhancing effect, and the sustained viral response (SVR) rate reaches up to 85-98% in patients with liver cirrhosis. In general, the chance of performing SVR with DAA in patients with compensated cirrhosis (Child-Pugh A) is comparable to non-cirrhotic patients. However, there is a risk for decompensation and acute liver failure during and after treatment. Patients with decompensated liver cirrhosis and advanced liver fibrosis may have greater benefit from antiviral therapy after liver transplantation. Conclusions: The data obtained from the analyzed studies suggest that DAA antiviral therapy prevents the progressive evolution of the disease towards hepatocellular carcinoma or decompensation. At the same time, a correct therapeutic approach and a permanent monitoring of these patients can improve the quality of life, significantly prolonging the years of life. Department of Infectious, Tropical Diseases and Medical Parasitology, Nicolae Testemitsanu State University of Medicine and Pharmacy, Chișinău, the Republic of Moldova Tue, 01 Jan 2019 00:00:00 GMT http://repository.usmf.md:80/xmlui/handle/20.500.12710/15272 2019-01-01T00:00:00Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/7584 Haemostatic system changes during pregnancy and puerperium Profire, Liliana Background: The activity in the hemostasis system is determined by two opposite processes that function simultaneously – blood clotting (fibrin clot formation) and fibrinolysis (the process of fibrin clot breakage). A normal balance between the processes of coagulation and fibrinolysis produces neither coagulation nor lysis, and vice versa, the imbalance of these processes is potentially dangerous in the development of coagulopathic or lytic events. Both systems (coagulation and fibrinolysis) undergo substantial changes in the physiological pregnancy, changes in an increase of coagulation factors concomitant with a decrease of anticoagulants and suppression in the fibrinolysis system. The predominance of prothrombotic activity gives the pregnancy a hypercoagulable status, with an increased risk of intravascular thrombi formation and thromboembolic complications (e.g. venous thrombosis, DIC syndrome). On the other hand, physiological hypercoagulation during pregnancy contributes to preventing the loss of blood during the immediate postpartum period by providing hemostasis in placental wounds and birth pathways. Conclusions: The hemostasis system in pregnant women is marked by an increase in coagulation at each stage (from endothelium to circulatory factors of coagulation) which presumes the risk of thrombo-embolic complications, and the inhibition in the fibrinolytic system prevents peripartum bleeding. Department of Obstetrics and Gynecology, Nicolae Testemitsanu State University of Medicine and Pharmacy Tue, 01 Jan 2019 00:00:00 GMT http://repository.usmf.md:80/xmlui/handle/20.500.12710/7584 2019-01-01T00:00:00Z